Viatris Inc vs Waste Management, Inc. — how do they compare? Viatris Inc trades at $17.64 (market cap $20.03B), while Waste Management, Inc. trades at $207.86 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 4.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Waste Management, Inc. for 130 Days on average.
| VTRS | WM | |
|---|---|---|
Market Cap | $20.03B | $83.98B |
Volume | 14,109,977 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $18.27 | $246.51 |
52-Week Low | $9.74 | $196.77 |
Typical Hold Time | 57 Days | 130 Days |
Enterprise Value | $32.15B | $106.78B |
Dividend Yield | 2.75% | 1.8% |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Waste Management (WM) trades at $207.71, down 0.59% on the day, with a bullish technical signal despite bearish moving averages. The company reported revenue of $25.20 billion in 2025, with net income of $2.71 billion and a net margin of 10.74%. Recent earnings show mixed results, with a miss in Q4 2025 but beats in Q1 and Q2 2026. Analyst consensus is strongly positive with 54.29% buy ratings and no sell recommendations.
WM's outlook remains favorable due to steady revenue growth, strong cash flow, and a resilient business model. Key risks include elevated debt levels and competitive pressures. The stock offers a reliable dividend, with the next payment of $0.95 scheduled for September 25, 2026. Investors should weigh solid fundamentals against debt concerns for long-term holdings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →